Cancer Cachexia Market By Treatment (Corticosteroids, Progesterones, Ghrelin (Gastric Peptide Hormone), Combination Therapy, and Others); By Application (Appetite Stimulation, Weight Loss Stabilization, and Others); By Distribution Channel (Hospitals & Clinics, Retail Pharmacies, and Others); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
Cancer cachexia is a syndrome that is characterised by an ongoing loss of skeletal muscle mass which happens due to reduced tolerance to treatment. A complex clinical condition, cachexia strikes more than 50% of patients suffering from different cancers. As it affects 60% to 80% of all patients suffering from the advanced stages of cancer, about 20% of all cancer patients die from cancer cachexia.
Increasing geriatric population is driving the growth of global cancer cachexia market. Prevalence of cancer cachexia is very high in patients with gastrointestinal cancer. During old age, body becomes weak, both from outside and inside, and the symptoms of cancer cachexia arise. In geriatric patients, simultaneous occurrence of cachexia, malnutrition, and sarcopenia has been observed. Anorexia and cachexia are known to diminish host defences in the geriatric population. All kinds of food, medicines, and health supplements are not suitable for all geriatric people, due to their medical conditions, allergies, and family history. Hence, treatment is difficult and thus, customized treatment for cancer cachexia is devised. Many pharmaceutical companies are investing significant resources into research and development (R&D) for the development of new cancer treatments focusing on geriatric population, which is anticipated to advance the growth of global cancer cachexia market over the forecast period.
The stringent regulatory requirements prevailing in the sector is restraining the growth of global cancer cachexia market. Manufacturers of cancer cachexia drugs are discouraged from investing in the market due to the long approval procedure by U.S. Food & Drugs Administration (FDA) and other respective regulatory authorities.
The COVID-19 pandemic has had a substantial impact on the overall healthcare sector, globally. Moreover, it has also led to a tremendous rise in concern because cancer patients are at a higher risk of being infected with COVID-19, since they are immunocompromised. Hence, their ability to fight against the infection is very low compared to other people. Also, if a cancer patient develops a COVID-19 infection, they are highly likely to suffer from multiple organ-related complications or cachexia. Initiatives and investments are being directed to address these challenges, which showcases positive growth prospects for global cancer cachexia market over the future years.
In terms of revenue, cancer cachexia market was valued at US$ 2117.60 Mn in 2020 growing at a CAGR of 4.9% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Cancer Cachexia Market Revenue & Forecast, (US $ Million), 2015 – 2029
Treatment Outlook:
On the basis of treatment, global cancer cachexia market covers corticosteroids, progesterones, ghrelin (gastric peptide hormone), combination therapy, and others. In 2020, the progesterones held the larger market share. Progesterone treatment is considered as an effective and safe option for the palliative treatment of cancer cachexia and many drugs are available for the same. The clinical side-effects of progestational agents increase only fat mass. Hence, compared to other agents, these side-effects are lesser. Apart from safety and effectiveness in cachexia treatment, the cost-effectiveness of the treatment is contributing to the market growth.
Application Outlook:
The application segment in the global cancer cachexia market in this report has been broadly segmented into appetite stimulation, weight loss stabilization, and others. In 2020, weight loss stabilization category held the largest market share. Loss of appetite is a very common symptom of cancer cachexia which can be noticed and hence attempted for early treatment by doctors. A person with cachexia may lose their desire to eat any kind food at all. Medications such as Dronabinol, glucocorticoids, and megestrol aid in certain medical conditions, including cancer cachexia and ailments. However, eating more does not stop the progression of symptoms. Nor it can improve muscle wasting. Some appetite stimulant that are commonly used by clinicians for the treatment of appetite loss include ghrelin mimetic, glucocorticoid, and megestrol acetate. For some male patients who may have low testosterone levels, androgen replacement therapy or use of an androgen receptor modulator can be considered. A progestational appetite stimulant, megestrol acetate has been effective for treatment of cancer cachexia as well as acquired immune deficiency syndrome (AIDS)-related cachexia. Growing incidences along with increasing investment towards the sector by the market participants is anticipated to accelerate the appetite stimulation segment in the global cancer cachexia market over the forecast period.
Distribution Channel Outlook:
This market report segments the distribution channels segment of global cancer cachexia market into hospitals & clinics, retail pharmacies, and others. Distribution of cancer cachexia medications through retail pharmacies have increased considerably, which is estimated to boost the segment’s growth over the forecast period. Ease of accessibility and convenience pertaining to the round-the-clock availability of these medications is contributing towards the segment’s growth in the global market.
Region Outlook:
In 2020, North America accounted for the highest share in the global cancer cachexia market. During the forecast period, Asia Pacific region is estimated to witness highest growth rate. Growing geriatric populations, high prevalence and incidence of cancer, increasing awareness among people, support from governments for cancer research, and presence of many qualified healthcare professionals for cancer supportive care in this region is aiding the region’s growth in the global market. Swiss pharmaceutical group, Helsinn has been focused on building quality cancer care and products useful for the treatment of rare diseases. It has recently launched Adlumiz (anamorelin) in Japan. Adlumiz (anamorelin) is useful for the treatment of cancer cachexia in malignant non-small cell lung cancer, colorectal cancer, gastric cancer, and pancreatic cancer.
Competitive Landscape Outlook:
The report provides both, qualitative and quantitative research of cancer cachexia market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some key players in the global cancer cachexia market are Actimed Therapeutics, Anuh Pharma Ltd., Aphios Corporation, Aveo Oncology, Fresenius Kabi, Helsinn Group, Merck KGaA, NGM Biopharmaceuticals, Pfizer Inc., R&D Systems Inc., Symbiotec Pharma Lab Pvt. Ltd., and Tetra Bio-Pharma amongst others.
Global Cancer Cachexia Market:
By Treatment
- Corticosteroids
- Progesterones
- Ghrelin (Gastric Peptide Hormone)
- Combination Therapy
- Others
By Application
- Appetite Stimulation
- Weight Loss Stabilization
- Others
By Distribution Channel
- Hospitals & Clinics
- Retail Pharmacies
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2019
1.2.2. Base
Year: 2020
1.2.3. Forecast
Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Cancer Cachexia Market
6. Market Synopsis:
Cancer Cachexia Market
7. Cancer Cachexia Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Cancer Cachexia Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Cancer Cachexia Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Cancer Cachexia Market
8. Global Cancer Cachexia Market Analysis and Forecasts, 2021 –
2029
8.1. Overview
8.1.1. Global
Cancer Cachexia Market Revenue (US$ Mn)
8.2. Global
Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Treatment
8.2.1. Corticosteroids
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2020
8.2.1.3. Market Forecast, 2021 - 2029
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market Estimation, 2015 - 2020
8.2.1.5.1.2. Market Forecast, 2021 - 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2020
8.2.1.5.2.2. Market Forecast, 2021 - 2029
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2020
8.2.1.5.3.2. Market Forecast, 2021 - 2029
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2020
8.2.1.5.4.2. Market Forecast, 2021 - 2029
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market Estimation, 2015 - 2020
8.2.1.5.5.2. Market Forecast, 2021 - 2029
8.2.2. Progesterones
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2020
8.2.2.3. Market Forecast, 2021 - 2029
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market Estimation, 2015 - 2020
8.2.2.5.1.2. Market Forecast, 2021 - 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2020
8.2.2.5.2.2. Market Forecast, 2021 - 2029
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2020
8.2.2.5.3.2. Market Forecast, 2021 - 2029
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2020
8.2.2.5.4.2. Market Forecast, 2021 - 2029
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market Estimation, 2015 - 2020
8.2.2.5.5.2. Market Forecast, 2021 - 2029
8.2.3. Ghrelin
(Gastric Peptide Hormone)
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2020
8.2.3.3. Market Forecast, 2021 - 2029
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market Estimation, 2015 - 2020
8.2.3.5.1.2. Market Forecast, 2021 - 2029
8.2.3.5.2. Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2020
8.2.3.5.2.2. Market Forecast, 2021 - 2029
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2020
8.2.3.5.3.2. Market Forecast, 2021 - 2029
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2020
8.2.3.5.4.2. Market Forecast, 2021 - 2029
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market Estimation, 2015 - 2020
8.2.3.5.5.2. Market Forecast, 2021 - 2029
8.2.4. Combination
Therapy
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2020
8.2.4.3. Market Forecast, 2021 - 2029
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market Estimation, 2015 - 2020
8.2.4.5.1.2. Market Forecast, 2021 - 2029
8.2.4.5.2. Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2020
8.2.4.5.2.2. Market Forecast, 2021 - 2029
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2020
8.2.4.5.3.2. Market Forecast, 2021 - 2029
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2020
8.2.4.5.4.2. Market Forecast, 2021 - 2029
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market Estimation, 2015 - 2020
8.2.4.5.5.2. Market Forecast, 2021 - 2029
8.2.5. Others
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 - 2020
8.2.5.3. Market Forecast, 2021 - 2029
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market Estimation, 2015 - 2020
8.2.5.5.1.2. Market Forecast, 2021 - 2029
8.2.5.5.2. Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2020
8.2.5.5.2.2. Market Forecast, 2021 - 2029
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2020
8.2.5.5.3.2. Market Forecast, 2021 - 2029
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2020
8.2.5.5.4.2. Market Forecast, 2021 - 2029
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market Estimation, 2015 - 2020
8.2.5.5.5.2. Market Forecast, 2021 - 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By
Treatment
9. Global Cancer Cachexia Market Analysis and Forecasts, 2021 –
2029
9.1. Overview
9.2. Global
Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Application
9.2.1. Appetite
Stimulation
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2020
9.2.1.3. Market Forecast, 2021 - 2029
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market Estimation, 2015 - 2020
9.2.1.5.1.2. Market Forecast, 2021 - 2029
9.2.1.5.2. Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2020
9.2.1.5.2.2. Market Forecast, 2021 - 2029
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2020
9.2.1.5.3.2. Market Forecast, 2021 - 2029
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2020
9.2.1.5.4.2. Market Forecast, 2021 - 2029
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market Estimation, 2015 - 2020
9.2.1.5.5.2. Market Forecast, 2021 - 2029
9.2.2. Weight
loss Stabilization
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2020
9.2.2.3. Market Forecast, 2021 - 2029
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market Estimation, 2015 - 2020
9.2.2.5.1.2. Market Forecast, 2021 - 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2020
9.2.2.5.2.2. Market Forecast, 2021 - 2029
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2020
9.2.2.5.3.2. Market Forecast, 2021 - 2029
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2020
9.2.2.5.4.2. Market Forecast, 2021 - 2029
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market Estimation, 2015 - 2020
9.2.2.5.5.2. Market Forecast, 2021 - 2029
9.2.3. Others
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2020
9.2.3.3. Market Forecast, 2021 - 2029
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market Estimation, 2015 - 2020
9.2.3.5.1.2. Market Forecast, 2021 - 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2020
9.2.3.5.2.2. Market Forecast, 2021 - 2029
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2020
9.2.3.5.3.2. Market Forecast, 2021 - 2029
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2020
9.2.3.5.4.2. Market Forecast, 2021 - 2029
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market Estimation, 2015 - 2020
9.2.3.5.5.2. Market Forecast, 2021 - 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By
Application
10. Global Cancer Cachexia Market Analysis and Forecasts, 2021 –
2029
10.1. Overview
10.2. Global
Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
10.2.1. Hospitals
and Clinics
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1.
Market Estimation, 2015 - 2020
10.2.1.5.1.2.
Market Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1.
Market Estimation, 2015 - 2020
10.2.1.5.2.2.
Market Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1.
Market Estimation, 2015 - 2020
10.2.1.5.3.2.
Market Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1.
Market Estimation, 2015 - 2020
10.2.1.5.4.2.
Market Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1.
Market Estimation, 2015 - 2020
10.2.1.5.5.2.
Market Forecast, 2021 - 2029
10.2.2. Retail
Pharmacies
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1.
Market Estimation, 2015 - 2020
10.2.2.5.1.2.
Market Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1.
Market Estimation, 2015 - 2020
10.2.2.5.2.2.
Market Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1.
Market Estimation, 2015 - 2020
10.2.2.5.3.2.
Market Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1.
Market Estimation, 2015 - 2020
10.2.2.5.4.2.
Market Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1.
Market Estimation, 2015 - 2020
10.2.2.5.5.2.
Market Forecast, 2021 - 2029
10.2.3. Others
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2020
10.2.3.3. Market Forecast, 2021 - 2029
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1.
Market Estimation, 2015 - 2020
10.2.3.5.1.2.
Market Forecast, 2021 - 2029
10.2.3.5.2. Europe
10.2.3.5.2.1.
Market Estimation, 2015 - 2020
10.2.3.5.2.2.
Market Forecast, 2021 - 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1.
Market Estimation, 2015 - 2020
10.2.3.5.3.2.
Market Forecast, 2021 - 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1.
Market Estimation, 2015 - 2020
10.2.3.5.4.2.
Market Forecast, 2021 - 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1.
Market Estimation, 2015 - 2020
10.2.3.5.5.2.
Market Forecast, 2021 - 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By
Distribution Channel
11. North America Cancer Cachexia Market Analysis and Forecasts,
2021 - 2029
11.1. Overview
11.1.1. North
America Cancer Cachexia Market Revenue (US$ Mn)
11.2. North
America Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Treatment
11.2.1. Corticosteroids
11.2.2. Progesterones
11.2.3. Ghrelin
(Gastric Peptide Hormone)
11.2.4. Combination
Therapy
11.2.5. Others
11.3. North
America Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Application
11.3.1. Appetite
Stimulation
11.3.2. Weight
loss Stabilization
11.3.3. Others
11.4. North
America Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
11.4.1. Hospitals
and Clinics
11.4.2. Retail
Pharmacies
11.4.3. Others
11.5. North
America Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By
Treatment
11.5.1.1.1. Corticosteroids
11.5.1.1.2. Progesterones
11.5.1.1.3. Ghrelin (Gastric Peptide Hormone)
11.5.1.1.4. Combination Therapy
11.5.1.1.5. Others
11.5.1.2. U.S Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By
Application
11.5.1.2.1. Appetite Stimulation
11.5.1.2.2. Weight loss Stabilization
11.5.1.2.3. Others
11.5.1.3. U.S Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
11.5.1.3.1. Hospitals and Clinics
11.5.1.3.2. Retail Pharmacies
11.5.1.3.3. Others
11.5.2. Canada
11.5.2.1. Canada Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Treatment
11.5.2.1.1. Corticosteroids
11.5.2.1.2. Progesterones
11.5.2.1.3. Ghrelin (Gastric Peptide Hormone)
11.5.2.1.4. Combination Therapy
11.5.2.1.5. Others
11.5.2.2. Canada Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Application
11.5.2.2.1. Appetite Stimulation
11.5.2.2.2. Weight loss Stabilization
11.5.2.2.3. Others
11.5.2.3. Canada Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
11.5.2.3.1. Hospitals and Clinics
11.5.2.3.2. Retail Pharmacies
11.5.2.3.3. Others
11.5.3. Mexico
11.5.3.1. Mexico Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Treatment
11.5.3.1.1. Corticosteroids
11.5.3.1.2. Progesterones
11.5.3.1.3. Ghrelin (Gastric Peptide Hormone)
11.5.3.1.4. Combination Therapy
11.5.3.1.5. Others
11.5.3.2. Mexico Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Application
11.5.3.2.1. Appetite Stimulation
11.5.3.2.2. Weight loss Stabilization
11.5.3.2.3. Others
11.5.3.3. Mexico Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
11.5.3.3.1. Hospitals and Clinics
11.5.3.3.2. Retail Pharmacies
11.5.3.3.3. Others
11.5.4. Rest of
North America
11.5.4.1. Rest of North America Cancer Cachexia Market Revenue (US$ Mn)
and Forecasts, By Treatment
11.5.4.1.1. Corticosteroids
11.5.4.1.2. Progesterones
11.5.4.1.3. Ghrelin (Gastric Peptide Hormone)
11.5.4.1.4. Combination Therapy
11.5.4.1.5. Others
11.5.4.2. Rest of North America Cancer Cachexia Market Revenue (US$ Mn)
and Forecasts, By Application
11.5.4.2.1. Appetite Stimulation
11.5.4.2.2. Weight loss Stabilization
11.5.4.2.3. Others
11.5.4.3. Rest of North America Cancer Cachexia Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
11.5.4.3.1. Hospitals and Clinics
11.5.4.3.2. Retail Pharmacies
11.5.4.3.3. Others
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By
Treatment
11.6.3. By
Application
11.6.4. By
Distribution Channel
12. Europe Cancer Cachexia Market Analysis and Forecasts, 2021 -
2029
12.1. Overview
12.1.1. Europe
Cancer Cachexia Market Revenue (US$ Mn)
12.2. Europe
Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Treatment
12.2.1. Corticosteroids
12.2.2. Progesterones
12.2.3. Ghrelin
(Gastric Peptide Hormone)
12.2.4. Combination
Therapy
12.2.5. Others
12.3. Europe
Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Application
12.3.1. Appetite
Stimulation
12.3.2. Weight
loss Stabilization
12.3.3. Others
12.4. Europe
Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.4.1. Hospitals
and Clinics
12.4.2. Retail
Pharmacies
12.4.3. Others
12.5. Europe
Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Treatment
12.5.1.1.1. Corticosteroids
12.5.1.1.2. Progesterones
12.5.1.1.3. Ghrelin (Gastric Peptide Hormone)
12.5.1.1.4. Combination Therapy
12.5.1.1.5. Others
12.5.1.2. France Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Application
12.5.1.2.1. Appetite Stimulation
12.5.1.2.2. Weight loss Stabilization
12.5.1.2.3. Others
12.5.1.3. France Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
12.5.1.3.1. Hospitals and Clinics
12.5.1.3.2. Retail Pharmacies
12.5.1.3.3. Others
12.5.2. The UK
12.5.2.1. The UK Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Treatment
12.5.2.1.1. Corticosteroids
12.5.2.1.2. Progesterones
12.5.2.1.3. Ghrelin (Gastric Peptide Hormone)
12.5.2.1.4. Combination Therapy
12.5.2.1.5. Others
12.5.2.2. The UK Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Application
12.5.2.2.1. Appetite Stimulation
12.5.2.2.2. Weight loss Stabilization
12.5.2.2.3. Others
12.5.2.3. The UK Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
12.5.2.3.1. Hospitals and Clinics
12.5.2.3.2. Retail Pharmacies
12.5.2.3.3. Others
12.5.3. Spain
12.5.3.1. Spain Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Treatment
12.5.3.1.1. Corticosteroids
12.5.3.1.2. Progesterones
12.5.3.1.3. Ghrelin (Gastric Peptide Hormone)
12.5.3.1.4. Combination Therapy
12.5.3.1.5. Others
12.5.3.2. Spain Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Application
12.5.3.2.1. Appetite Stimulation
12.5.3.2.2. Weight loss Stabilization
12.5.3.2.3. Others
12.5.3.3. Spain Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
12.5.3.3.1. Hospitals and Clinics
12.5.3.3.2. Retail Pharmacies
12.5.3.3.3. Others
12.5.4. Germany
12.5.4.1. Germany Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Treatment
12.5.4.1.1. Corticosteroids
12.5.4.1.2. Progesterones
12.5.4.1.3. Ghrelin (Gastric Peptide Hormone)
12.5.4.1.4. Combination Therapy
12.5.4.1.5. Others
12.5.4.2. Germany Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Application
12.5.4.2.1. Appetite Stimulation
12.5.4.2.2. Weight loss Stabilization
12.5.4.2.3. Others
12.5.4.3. Germany Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
12.5.4.3.1. Hospitals and Clinics
12.5.4.3.2. Retail Pharmacies
12.5.4.3.3. Others
12.5.5. Italy
12.5.5.1. Italy Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Treatment
12.5.5.1.1. Corticosteroids
12.5.5.1.2. Progesterones
12.5.5.1.3. Ghrelin (Gastric Peptide Hormone)
12.5.5.1.4. Combination Therapy
12.5.5.1.5. Others
12.5.5.2. Italy Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Application
12.5.5.2.1. Appetite Stimulation
12.5.5.2.2. Weight loss Stabilization
12.5.5.2.3. Others
12.5.5.3. Italy Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
12.5.5.3.1. Hospitals and Clinics
12.5.5.3.2. Retail Pharmacies
12.5.5.3.3. Others
12.5.6. Nordic
Countries
12.5.6.1. Nordic Countries Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Treatment
12.5.6.1.1. Corticosteroids
12.5.6.1.2. Progesterones
12.5.6.1.3. Ghrelin (Gastric Peptide Hormone)
12.5.6.1.4. Combination Therapy
12.5.6.1.5. Others
12.5.6.2. Nordic Countries Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.6.2.1. Appetite Stimulation
12.5.6.2.2. Weight loss Stabilization
12.5.6.2.3. Others
12.5.6.3. Nordic Countries Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
12.5.6.3.1. Hospitals and Clinics
12.5.6.3.2. Retail Pharmacies
12.5.6.3.3. Others
12.5.6.4. Nordic Countries Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux Union Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Treatment
12.5.7.1.1. Corticosteroids
12.5.7.1.2. Progesterones
12.5.7.1.3. Ghrelin (Gastric Peptide Hormone)
12.5.7.1.4. Combination Therapy
12.5.7.1.5. Others
12.5.7.2. Benelux Union Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.7.2.1. Appetite Stimulation
12.5.7.2.2. Weight loss Stabilization
12.5.7.2.3. Others
12.5.7.3. Benelux Union Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
12.5.7.3.1. Hospitals and Clinics
12.5.7.3.2. Retail Pharmacies
12.5.7.3.3. Others
12.5.7.4. Benelux Union Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest of Europe Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Treatment
12.5.8.1.1. Corticosteroids
12.5.8.1.2. Progesterones
12.5.8.1.3. Ghrelin (Gastric Peptide Hormone)
12.5.8.1.4. Combination Therapy
12.5.8.1.5. Others
12.5.8.2. Rest of Europe Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.8.2.1. Appetite Stimulation
12.5.8.2.2. Weight loss Stabilization
12.5.8.2.3. Others
12.5.8.3. Rest of Europe Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
12.5.8.3.1. Hospitals and Clinics
12.5.8.3.2. Retail Pharmacies
12.5.8.3.3. Others
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By Treatment
12.6.3. By
Application
12.6.4. By
Distribution Channel
13. Asia Pacific Cancer Cachexia Market Analysis and Forecasts,
2021 - 2029
13.1. Overview
13.1.1. Asia
Pacific Cancer Cachexia Market Revenue (US$ Mn)
13.2. Asia
Pacific Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Treatment
13.2.1. Corticosteroids
13.2.2. Progesterones
13.2.3. Ghrelin
(Gastric Peptide Hormone)
13.2.4. Combination
Therapy
13.2.5. Others
13.3. Asia
Pacific Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Application
13.3.1. Appetite
Stimulation
13.3.2. Weight
loss Stabilization
13.3.3. Others
13.4. Asia
Pacific Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.4.1. Hospitals
and Clinics
13.4.2. Retail
Pharmacies
13.4.3. Others
13.5. Asia
Pacific Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Treatment
13.5.1.1.1. Corticosteroids
13.5.1.1.2. Progesterones
13.5.1.1.3. Ghrelin (Gastric Peptide Hormone)
13.5.1.1.4. Combination Therapy
13.5.1.1.5. Others
13.5.1.2. China Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.1.2.1. Appetite Stimulation
13.5.1.2.2. Weight loss Stabilization
13.5.1.2.3. Others
13.5.1.3. China Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
13.5.1.3.1. Hospitals and Clinics
13.5.1.3.2. Retail Pharmacies
13.5.1.3.3. Others
13.5.2. Japan
13.5.2.1. Japan Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Treatment
13.5.2.1.1. Corticosteroids
13.5.2.1.2. Progesterones
13.5.2.1.3. Ghrelin (Gastric Peptide Hormone)
13.5.2.1.4. Combination Therapy
13.5.2.1.5. Others
13.5.2.2. Japan Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.2.2.1. Appetite Stimulation
13.5.2.2.2. Weight loss Stabilization
13.5.2.2.3. Others
13.5.2.3. Japan Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
13.5.2.3.1. Hospitals and Clinics
13.5.2.3.2. Retail Pharmacies
13.5.2.3.3. Others
13.5.3. India
13.5.3.1. India Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Treatment
13.5.3.1.1. Corticosteroids
13.5.3.1.2. Progesterones
13.5.3.1.3. Ghrelin (Gastric Peptide Hormone)
13.5.3.1.4. Combination Therapy
13.5.3.1.5. Others
13.5.3.2. India Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.3.2.1. Appetite Stimulation
13.5.3.2.2. Weight loss Stabilization
13.5.3.2.3. Others
13.5.3.3. India Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
13.5.3.3.1. Hospitals and Clinics
13.5.3.3.2. Retail Pharmacies
13.5.3.3.3. Others
13.5.4. New
Zealand
13.5.4.1. New Zealand Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.5.4.1.1. Corticosteroids
13.5.4.1.2. Progesterones
13.5.4.1.3. Ghrelin (Gastric Peptide Hormone)
13.5.4.1.4. Combination Therapy
13.5.4.1.5. Others
13.5.4.2. New Zealand Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.4.2.1. Appetite Stimulation
13.5.4.2.2. Weight loss Stabilization
13.5.4.2.3. Others
13.5.4.3. New Zealand Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.5.4.3.1. Hospitals and Clinics
13.5.4.3.2. Retail Pharmacies
13.5.4.3.3. Others
13.5.5. Australia
13.5.5.1. Australia Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.5.5.1.1. Corticosteroids
13.5.5.1.2. Progesterones
13.5.5.1.3. Ghrelin (Gastric Peptide Hormone)
13.5.5.1.4. Combination Therapy
13.5.5.1.5. Others
13.5.5.2. Australia Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.5.2.1. Appetite Stimulation
13.5.5.2.2. Weight loss Stabilization
13.5.5.2.3. Others
13.5.5.3. Australia Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.5.5.3.1. Hospitals and Clinics
13.5.5.3.2. Retail Pharmacies
13.5.5.3.3. Others
13.5.6. South
Korea
13.5.6.1. South Korea Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.5.6.1.1. Corticosteroids
13.5.6.1.2. Progesterones
13.5.6.1.3. Ghrelin (Gastric Peptide Hormone)
13.5.6.1.4. Combination Therapy
13.5.6.1.5. Others
13.5.6.2. South Korea Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.6.2.1. Appetite Stimulation
13.5.6.2.2. Weight loss Stabilization
13.5.6.2.3. Others
13.5.6.3. South Korea Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.5.6.3.1. Hospitals and Clinics
13.5.6.3.2. Retail Pharmacies
13.5.6.3.3. Others
13.5.7. Southeast
Asia
13.5.7.1. Southeast Asia Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.5.7.1.1. Corticosteroids
13.5.7.1.2. Progesterones
13.5.7.1.3. Ghrelin (Gastric Peptide Hormone)
13.5.7.1.4. Combination Therapy
13.5.7.1.5. Others
13.5.7.2. Southeast Asia Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.7.2.1. Appetite Stimulation
13.5.7.2.2. Weight loss Stabilization
13.5.7.2.3. Others
13.5.7.3. Southeast Asia Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.5.7.3.1. Hospitals and Clinics
13.5.7.3.2. Retail Pharmacies
13.5.7.3.3. Others
13.5.7.4. Southeast Asia Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest of Asia Pacific Cancer Cachexia Market Revenue (US$ Mn)
and Forecasts, By Treatment
13.5.8.1.1. Corticosteroids
13.5.8.1.2. Progesterones
13.5.8.1.3. Ghrelin (Gastric Peptide Hormone)
13.5.8.1.4. Combination Therapy
13.5.8.1.5. Others
13.5.8.2. Rest of Asia Pacific Cancer Cachexia Market Revenue (US$ Mn)
and Forecasts, By Application
13.5.8.2.1. Appetite Stimulation
13.5.8.2.2. Weight loss Stabilization
13.5.8.2.3. Others
13.5.8.3. Rest of Asia Pacific Cancer Cachexia Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
13.5.8.3.1. Hospitals and Clinics
13.5.8.3.2. Retail Pharmacies
13.5.8.3.3. Others
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By
Treatment
13.6.3. By
Application
13.6.4. By
Distribution Channel
14. Middle East and Africa Cancer Cachexia Market Analysis and
Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Middle
East and Africa Cancer Cachexia Market Revenue (US$ Mn)
14.2. Middle
East and Africa Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By
Treatment
14.2.1. Corticosteroids
14.2.2. Progesterones
14.2.3. Ghrelin
(Gastric Peptide Hormone)
14.2.4. Combination
Therapy
14.2.5. Others
14.3. Middle
East and Africa Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By
Application
14.3.1. Appetite
Stimulation
14.3.2. Weight
loss Stabilization
14.3.3. Others
14.4. Middle
East and Africa Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.4.1. Hospitals
and Clinics
14.4.2. Retail
Pharmacies
14.4.3. Others
14.5. Middle
East and Africa Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By
Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi Arabia Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Treatment
14.5.1.1.1. Corticosteroids
14.5.1.1.2. Progesterones
14.5.1.1.3. Ghrelin (Gastric Peptide Hormone)
14.5.1.1.4. Combination Therapy
14.5.1.1.5. Others
14.5.1.2. Saudi Arabia Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.1.2.1. Appetite Stimulation
14.5.1.2.2. Weight loss Stabilization
14.5.1.2.3. Others
14.5.1.3. Saudi Arabia Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.5.1.3.1. Hospitals and Clinics
14.5.1.3.2. Retail Pharmacies
14.5.1.3.3. Others
14.5.2. UAE
14.5.2.1. UAE Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By
Treatment
14.5.2.1.1. Corticosteroids
14.5.2.1.2. Progesterones
14.5.2.1.3. Ghrelin (Gastric Peptide Hormone)
14.5.2.1.4. Combination Therapy
14.5.2.1.5. Others
14.5.2.2. UAE Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By
Application
14.5.2.2.1. Appetite Stimulation
14.5.2.2.2. Weight loss Stabilization
14.5.2.2.3. Others
14.5.2.3. UAE Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.5.2.3.1. Hospitals and Clinics
14.5.2.3.2. Retail Pharmacies
14.5.2.3.3. Others
14.5.3. Egypt
14.5.3.1. Egypt Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Treatment
14.5.3.1.1. Corticosteroids
14.5.3.1.2. Progesterones
14.5.3.1.3. Ghrelin (Gastric Peptide Hormone)
14.5.3.1.4. Combination Therapy
14.5.3.1.5. Others
14.5.3.2. Egypt Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Application
14.5.3.2.1. Appetite Stimulation
14.5.3.2.2. Weight loss Stabilization
14.5.3.2.3. Others
14.5.3.3. Egypt Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
14.5.3.3.1. Hospitals and Clinics
14.5.3.3.2. Retail Pharmacies
14.5.3.3.3. Others
14.5.4. Kuwait
14.5.4.1. Kuwait Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Treatment
14.5.4.1.1. Corticosteroids
14.5.4.1.2. Progesterones
14.5.4.1.3. Ghrelin (Gastric Peptide Hormone)
14.5.4.1.4. Combination Therapy
14.5.4.1.5. Others
14.5.4.2. Kuwait Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Application
14.5.4.2.1. Appetite Stimulation
14.5.4.2.2. Weight loss Stabilization
14.5.4.2.3. Others
14.5.4.3. Kuwait Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
14.5.4.3.1. Hospitals and Clinics
14.5.4.3.2. Retail Pharmacies
14.5.4.3.3. Others
14.5.5. South
Africa
14.5.5.1. South Africa Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Treatment
14.5.5.1.1. Corticosteroids
14.5.5.1.2. Progesterones
14.5.5.1.3. Ghrelin (Gastric Peptide Hormone)
14.5.5.1.4. Combination Therapy
14.5.5.1.5. Others
14.5.5.2. South Africa Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.5.2.1. Appetite Stimulation
14.5.5.2.2. Weight loss Stabilization
14.5.5.2.3. Others
14.5.5.3. South Africa Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.5.5.3.1. Hospitals and Clinics
14.5.5.3.2. Retail Pharmacies
14.5.5.3.3. Others
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Cancer Cachexia Market
Revenue (US$ Mn) and Forecasts, By Treatment
14.5.6.1.1. Corticosteroids
14.5.6.1.2. Progesterones
14.5.6.1.3. Ghrelin (Gastric Peptide Hormone)
14.5.6.1.4. Combination Therapy
14.5.6.1.5. Others
14.5.6.2. Rest of Middle East & Africa Cancer Cachexia Market
Revenue (US$ Mn) and Forecasts, By Application
14.5.6.2.1. Appetite Stimulation
14.5.6.2.2. Weight loss Stabilization
14.5.6.2.3. Others
14.5.6.3. Rest of Middle East & Africa Cancer Cachexia Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.5.6.3.1. Hospitals and Clinics
14.5.6.3.2. Retail Pharmacies
14.5.6.3.3. Others
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By
Treatment
14.6.3. By
Application
14.6.4. By
Distribution Channel
15. Latin America Cancer Cachexia Market Analysis and Forecasts,
2021 - 2029
15.1. Overview
15.1.1. Latin
America Cancer Cachexia Market Revenue (US$ Mn)
15.2. Latin
America Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Treatment
15.2.1. Corticosteroids
15.2.2. Progesterones
15.2.3. Ghrelin
(Gastric Peptide Hormone)
15.2.4. Combination
Therapy
15.2.5. Others
15.3. Latin
America Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Application
15.3.1. Appetite
Stimulation
15.3.2. Weight
loss Stabilization
15.3.3. Others
15.4. Latin
America Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
15.4.1. Hospitals
and Clinics
15.4.2. Retail
Pharmacies
15.4.3. Others
15.5. Latin
America Cancer Cachexia Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Treatment
15.5.1.1.1. Corticosteroids
15.5.1.1.2. Progesterones
15.5.1.1.3. Ghrelin (Gastric Peptide Hormone)
15.5.1.1.4. Combination Therapy
15.5.1.1.5. Others
15.5.1.2. Brazil Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Application
15.5.1.2.1. Appetite Stimulation
15.5.1.2.2. Weight loss Stabilization
15.5.1.2.3. Others
15.5.1.3. Brazil Cancer Cachexia Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
15.5.1.3.1. Hospitals and Clinics
15.5.1.3.2. Retail Pharmacies
15.5.1.3.3. Others
15.5.2. Argentina
15.5.2.1. Argentina Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Treatment
15.5.2.1.1. Corticosteroids
15.5.2.1.2. Progesterones
15.5.2.1.3. Ghrelin (Gastric Peptide Hormone)
15.5.2.1.4. Combination Therapy
15.5.2.1.5. Others
15.5.2.2. Argentina Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Application
15.5.2.2.1. Appetite Stimulation
15.5.2.2.2. Weight loss Stabilization
15.5.2.2.3. Others
15.5.2.3. Argentina Cancer Cachexia Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.5.2.3.1. Hospitals and Clinics
15.5.2.3.2. Retail Pharmacies
15.5.2.3.3. Others
15.5.3. Rest of
Latin America
15.5.3.1. Rest of Latin America Cancer Cachexia Market Revenue (US$ Mn)
and Forecasts, By Treatment
15.5.3.1.1. Corticosteroids
15.5.3.1.2. Progesterones
15.5.3.1.3. Ghrelin (Gastric Peptide Hormone)
15.5.3.1.4. Combination Therapy
15.5.3.1.5. Others
15.5.3.2. Rest of Latin America Cancer Cachexia Market Revenue (US$ Mn)
and Forecasts, By Application
15.5.3.2.1. Appetite Stimulation
15.5.3.2.2. Weight loss Stabilization
15.5.3.2.3. Others
15.5.3.3. Rest of Latin America Cancer Cachexia Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
15.5.3.3.1. Hospitals and Clinics
15.5.3.3.2. Retail Pharmacies
15.5.3.3.3. Others
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By
Treatment
15.6.3. By
Application
15.6.4. By
Distribution Channel
16. Competitive Benchmarking
16.1. Market
Share Analysis, 2020
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player Profiles
17.1. Actimed
Therapeutics
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Anuh Pharma Ltd.
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business Strategies
17.3. Aphios
Corporation
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. Aveo
Oncology
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. Fresenius
Kabi
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. Helsinn
Group
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. Merck
KGaA
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. NGM
Biopharmaceuticals
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. Pfizer
Inc.
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. R&D Systems, Inc.
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business Strategies
17.11. Symbiotec Pharma Lab Pvt. Ltd.
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key
Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business Strategies
17.12. Tetra
Bio-Pharma
17.12.1. Company
Details
17.12.2. Company
Overview
17.12.3. Product
Offerings
17.12.4. Key
Developments
17.12.5. Financial
Analysis
17.12.6. SWOT
Analysis
17.12.7. Business
Strategies
18. Key Findings
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.